Navigation Links
Drugs to combat anemia in cancer patients increase risk of death
Date:4/30/2009

OTTAWA, ONTARIO, CANADA The use of drugs to encourage red blood cell formation (erythropoiesis-stimulating agents) in cancer patients with anemia increases the risk of death and serious adverse events such as blood clots, found a new study in CMAJ.

While the relative increased risk of death was only 15-16%, because of the high mortality rates in cancer patients this increase might translate into significant numbers of people.

"These findings suggest that erythropoiesis-stimulating agents should not be routinely used as an alternative to blood transfusion in patients with chemotherapy-induced anemia unless future studies document safety and clinical benefits in this population," write Dr. Marcello Tonelli from the University of Alberta and coauthors.

Anemia in cancer patients can develop because of the cancer itself or because of treatments such as chemotherapy. Treatment with agents to stimulate red blood cell formation has been widely used to improve quality of life for many patients and as an alternative to blood transfusions. However, these agents are expensive and reimbursement policies in Canada vary across provinces and territories.

The study, a meta-analysis of 52 clinical trials with 12,006 participants, was based on work done for the Canadian Agency for Drugs and Technologies in Health (CADTH) to summarize the benefits and harms of these agents in adults with cancer-related anemia.

The findings, which are consistent with studies from the United States and the United Kingdom, provide important information for clinicians treating cancer patients and for Canadian policy makers regarding drug reimbursement plans.

"Our findings suggest that existing practice guidelines should be revised to recommend against the routine use of erythropoiesis-stimulating agents as an alternative to blood transfusion in patients with cancer," conclude the authors. Th
'/>"/>

Contact: Kim Barnhardt
kim.barnhardt@cmaj.ca
613-520-7116 x2224
Canadian Medical Association Journal
Source:Eurekalert

Page: 1 2

Related medicine news :

1. New review suggests caution on drugs to raise good cholesterol
2. Can cancer drugs combine forces?
3. Study provides hope that some transplant patients could live free of antirejection drugs
4. Study provides hope that some transplant patients could live free of anti-rejection drugs
5. RA Drugs Linked to Slight Skin Cancer Risk
6. Report on patients access to cancer drugs uses flawed methods to reached flawed conclusions
7. Rock N Roll: Sex, Drugs and an Early Exit
8. Australian-led international study shows blood pressure drugs cut death rate in type 2 diabetes
9. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
10. Are Bargaining Groups Hired by Independent Drugstores Causing Payment Delays to Pharmacies?
11. 2 drugs equally effective for heart patients undergoing angioplasty, Mayo study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... ... August 03, 2015 , ... Catalent Pharma Solutions, the ... and consumer health products, today welcomed the announcement by OPKO Health that the ... for a new treatment for chronic kidney disease (CKD) and vitamin D insufficiency, ...
(Date:8/3/2015)... ... August 03, 2015 , ... Novatus, Inc. today launched ... solution, as well as announced the date of its next major release. , ... contract management tasks as well as enhancements to the customer experience. Users ...
(Date:8/3/2015)... ... August 03, 2015 , ... Sensato and ... “Designing Secure Healthcare Systems” This three-day, highly interactive and immersive workshop, has ... with access to the tactics, techniques and practices required to design and develop ...
(Date:8/3/2015)... CA (PRWEB) , ... August 03, 2015 , ... A ... Pain: Injection of Stem Cells Found to Release Natural Painkiller That Can Last 'For ... in patients. According to the report, the new study showed that harvesting stem cell-rich ...
(Date:8/3/2015)... CA (PRWEB) , ... August 03, 2015 , ... ... global insurance brokerage firm, announced today that Joe Williams has joined its growing ... sales, and delivering HUB's differentiated service model to his clients. Mr. Williams will ...
Breaking Medicine News(10 mins):Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3Health News:Novatus Unveils Milestone Software Release 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2
... Following the,successful OCEANE bond issue, completed last Friday, ... Quantel signed on September 18th a,definitive agreement with ... GmbH, its subsidiary specialized in,dermatology-aesthetics lasers. Conditions ... a EUR4.6 million fixed portion and a,variable portion ...
... Sept. 19 If you,ve been experiencing watery,eyes and ... the,rise in the U.S., with an estimated 50 million ... to the tune of 3 billion,dollars a year, often ... say in-vitro blood tests, the latest generation of,allergy tests, ...
... for diseases such as diabetes and Alzheimer,s , WEDNESDAY, Sept. ... adult stem cells from the testes of male mice into ... contractile cardiac tissue, and brain cells. , If the same ... they may offer a source of new therapies to treat ...
... 20, 2007) -- Easily accessed and plentiful, adult stem cells ... to create a wide range of tissue types to help ... controversial embryonic stem cells. , That,s the promise of a ... Cornell Medical College in New York City, who report their ...
... access to high-quality, evidence-based care for behavioral health,conditions ... The,"Mental Health Parity Act of 2007" would require ... parity with respect to all financial,requirements and all ... "AHIP applauds the Senate for coming together ...
... When Michael Murphy of,Seymour, Iowa, was handed the ... of the September 15th Iowa vs. Iowa State,football game, ... Ride, Iowa",raffle. The Iowa Farm Bureau donated all proceeds ... (tickets were $10 each) to the American,Lung Association of ...
Cached Medicine News:Health News:QUANTEL Finalizes the Acquisition of WaveLight Aesthetic GmbH 2Health News:Stem Cells From Testes Produce Wide Range of Tissue Types 2Health News:Stem cells in adult testes provide alternative to embryonic stem cells for organ regeneration 2Health News:Stem cells in adult testes provide alternative to embryonic stem cells for organ regeneration 3Health News:Stem cells in adult testes provide alternative to embryonic stem cells for organ regeneration 4Health News:Renewable Fuel Chopper Raffle Nets $113,000 for American Lung Association Clean Air Choice Program 2
(Date:8/3/2015)... CORAL SPRINGS, Florida , August 3, ... and development agreements between biotech companies, military ... biotech solutions & therapies with regards to ... to positive clinical enhancements for regenerative medicine ... with recent developments, partnerships and advancements in ...
(Date:8/3/2015)... -- Biosensors International Group, Ltd. ("Biosensors" or the ... a developer, manufacturer and marketer of innovative medical ... fiscal quarter ended 30 June 2015 ("Q1 FY16"). ... , Biosensors continued to make ... by lower operating expenses and operational improvement. Operating ...
(Date:8/3/2015)... -- Array BioPharma Inc. (NASDAQ: ARRY ) today ... year of its fiscal year ended June 30, ... Array, noted, "Binimetinib and encorafenib, two innovative oncology ... regulatory submissions in 2016. Additional data shared over ... cancer further validate the value of these programs ...
Breaking Medicine Technology:Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 2Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 3Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 4Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 5Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 6Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 2Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 3Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 4Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 5Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 2Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 3Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 4Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 5Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 7Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 8Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 9Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 10Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 11Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 12
Uvex Patriot Frame...
... are designed with the safety and comfort of ... RS-520 (also called SF-6) leaded glass, the industry ... standards, as set for optical clarity, visible light ... eyewear is protecting your eyes, it also helps ...
... Goggles fit over glasses ... by the whole department! ... 1.0 mm leaded glass ... scatter radiation protection. Clear ...
Qualcraft™ Radiation Protection Eyewear, Metal, Bifocal. Provides maximum comfort and eye protection! Plano (nonprescription). Black with bronze temple bar....
Medicine Products: